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Abstract: Despite several therapeutic advances, malignant melanoma still remains a fatal disease for
which novel and long-term curative treatments are needed. The successful development of innovative
therapies strongly depends on the availability of appropriate pre-clinical models. For this purpose,
several mouse models holding the promise to provide insight into molecular biology and clinical
behavior of melanoma have been generated. The most relevant ones and their contribution for the
advancement of therapeutic approaches for the treatment of human melanoma patients will be here
summarized. However, as models, mice do not recapitulate all the features of human melanoma,
thus their strengths and weaknesses need to be carefully identified and considered for the translation
of the results into the human clinics. In this panorama, the concept of comparative oncology acquires
a priceless value. The revolutionary importance of spontaneous canine melanoma as a translational
model for the pre-clinical investigation of melanoma progression and treatment will be here discussed,
with a special consideration to the development of innovative immunotherapeutic approaches.
Keywords: melanoma; pre-clinical models; immunotherapy; canine melanoma; comparative
oncology; CSPG4
1. Introduction
Melanoma is the sixth most common leading cancer worldwide and its incidence is continuously
rising [1]. While in its early stages melanoma is highly curable, the management of metastatic
melanoma patients has been historically exceptionally challenging, with extremely poor survival
rate [2,3]. Thus, the identification of innovative and long-term curative treatments is still an unmet need.
For this purpose, researchers have looked for models that could represent melanoma development
and progression in a realistic way.
For many years, the study of melanoma cell biology and anti-melanoma drug activity has been
performed exploiting cultured tumor cell lines in vitro. However, this model is not suitable for an
accurate reproduction of melanoma complexity, lacking several fundamental aspects. Growing in
a two-dimensional setting, in vitro cell lines do not mimic the three-dimensional architecture of a
melanoma, neither its heterogeneity or its dynamic connection with the microenvironment. Indeed,
during the natural evolution of the tumor, melanoma cells establish complex interactions with the
surrounding cells, including immune ones, which play a fundamental role in shaping melanoma
evolution [4,5].
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The investigation of in vivo pre-clinical models could provide a valuable tool for gaining insight
into melanoma development, progression and clinical behavior in a more realistic way which retains
most of the principal hallmarks of cancer [6–8]. In this panorama, mice developing melanoma
have been generated and widely explored. Some pre-clinical studies in mouse models have been
of paramount importance for the human clinics, but several failed in the translation from bench
to bedside [9]. Spontaneous canine melanoma could represent a revolution in the field, allowing
to overcome the limitations of pre-clinical mouse models. Moreover, the evaluation of therapeutic
approaches to fight against melanoma in dogs represents a valuable option to accelerate the translation
of pre-clinical studies from the veterinary to the human clinical oncology, with the benefit for both
species [7]. The principal pre-clinical mouse models and their contribution in the advancement in
therapeutic approaches for human melanoma treatment will be here summarized. A special focus
will be dedicated to the emerging importance of immunotherapeutic studies performed in canine
melanoma patients.
2. The Strength of Mouse Models: Testing of Targeted Therapies against Melanoma
Mouse models of melanoma have come to the stage, providing instrumental information on this
complex disease. They have allowed a better understanding of melanoma pathobiology through the
(i) identification and characterization of specific key tumor suppressor genes and oncogenes involved
in melanoma biology; (ii) the testing of novel therapeutic agents to be applied in the treatment of
melanoma patients and (iii) the elucidation of the role of circulating exosomes (EXs) as new predictors
or early markers of metastatic disease.
By definition, models will not replicate all aspects of human melanoma. However, in multiple
settings, mice really served as little patients, successfully linking bench to bedside. In the following
sections, mouse models used to reproduce the more relevant genetic aberrations identified in human
melanomas will be discussed.
The genetic characterization of melanoma is still incomplete. Nevertheless, molecular analysis
of both familial and sporadic cutaneous melanomas has led to the identification of recurrent somatic
mutations in several key genes relevant for cell proliferation (BRAF, NRAS and NF1), growth
and metabolism (PTEN and KIT), resistance to apoptosis (TP53), cell cycle control (CDKN2A) and
replicative lifespan (TERT) [10]. A different mutational pattern has been highlighted in melanomas
arisen from other tissues, including the uvea of the eye and within mucous membranes, characterized
by frequent mutations in the guanine-nucleotide binding protein G subunit alpha Q (GNAQ) and
alpha 11 (GNA11), in the tumor suppressor gene BRCA1 associated protein 1 (BAP1) or in splicing
factor 3b subunit 1 (SF3B1). Most of these genetic aberrations have been reproduced in mouse
models, in order to better elucidate their functions in melanoma progression and their role as potential
therapeutic targets [11].
2.1. Pre-Clinical Modeling of BRAF in Mice
In 2002, for the first time, Davies and collaborators reported the presence of the—now
well-known—somatic point mutation V600E in the BRAF gene in human malignant melanomas [12].
It was the beginning of accumulating investigations that validated the expression of BRAFV600E in over
50% of human melanoma patients, suggesting its causal role in melanoma initiation, development,
and progression [13–16]. It was the starting of hope for a potential revolution in the management
of the majority of melanoma patients thanks to the exploration of target-specific therapies directed
against BRAFV600E. As a straight consequence, a number of murine models were developed, including
genetically engineered mouse (GEM) and human xenograft models which independently proved the
oncogenic role and importance of BRAFV600E mutation in melanomagenesis.
In particular, in 2009, Dhomen and collaborators developed a GEM model (GEMM) of BRAFV600E
melanoma (Tyr::CreERT2, BRAFV600E), whose tumors recapitulate human amelanotic/oligomelanotic
malignant melanoma. This GEMM was extremely helpful in corroborating the driving role of
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the mutated BRAF in melanomagenesis [17]. Moreover, Viros et al. demonstrated in these mice
that single or repeated doses of UV radiation, mimicking mild sunburn in humans, induced an
accelerated BRAFV600E-driven melanomagenesis, strongly supporting the role of UV in melanoma
development [18]. However, because of the long latency required for the development of tumors in this
GEMM, several groups demonstrated independently that additional genetic lesions could cooperate
with the BRAFV600E mutation in accelerating melanoma initiation and progression. Indeed, the
association of p16INK4a or p16INK4A/p19ARF loss, as well as, Pten silencing, significantly increase the
incidence, reduce the latency and dramatically increase the metastatic behavior of tumors in BRAFV600E
GEMM [19–21]. More recently, Perna and coauthors generated a GEMM with a conditional expression
of BRAFV618E mutation (analogous to BRAFV600E in humans) in mouse melanocytes, supporting the
previous findings that oncogenic BRAF alone is sufficient to initiate melanomagenesis, even if with
incomplete penetrance and prolonged latency [22]. Notably, the treatment of these mice with a BRAF
inhibitor (PLX4720) resulted in tumor regression followed by relapse, mimicking the human clinical
condition. And the analysis of recurrent melanomas allowed the identification of novel candidates
responsible for the resistance to the BRAF inhibitor PLX4720, with strong potential implications into the
human clinics [22]. Dankort et al. took advantages of their BRAFV600E; Pten−/− metastatic melanoma
GEMM to demonstrate the importance of targeting key signaling pathways linked to these genetic
aberrations. Indeed, in this GEMM, the inhibition of mTorc1 by using Rapamycin or of MEK1/2 by
using PD325901, prevented melanoma development, but only during drug administration. The results
obtained suggested that melanoma-initiating cells survive the treatments and induce tumor relapse as
soon as the drug is stopped. Nevertheless, the combined treatment with Rapamycin and PD325901 led
to shrinkage of BRAFV600E; Pten−/− established melanomas [21].
Overall, these GEMMs provide an excellent system not only to study the role of BRAFV600E
in melanoma progression but also to pre-clinically evaluate the consequences of its direct or
indirect targeting.
Despite the availability of GEMMs, however, the vast majority of the pre-clinical studies on
BRAFV600E role and targeting have been performed in xenograft models, based on the engraftment
of human melanoma cells into immunodeficient mice. Taking advantage of these models, early after
the identification of the BRAFV600E mutation in human melanomas, the validation of its oncogenic
role in the early stage of tumor progression was achieved by expressing BRAFV600E in cultured
melanocytes. The expression of the mutated BRAFV600E made the melanocytes capable to give rise to
tumors when injected subcutaneously in nude mice, conversely to the BRAFwt counterpart cell line
that did not grow [23]. Since then, tons of studies have exploited the xenotransplantation of BRAFV600E
human melanoma cells into nude mice which allowed a relatively easy and quick evaluation of the
oncogenic role of activated BRAF and the potential of its targeting. Among the most clinically relevant
studies, Tsai and collaborators proved the anti-tumor potential of the mutated-BRAF selective inhibitor
(PLX4720) in BRAFV600E-dependent tumor xenograft models, inducing a significant tumor growth
delay and even regression [24]. Later on, several groups, working on different BRAFV600E-expressing
melanoma xenograft models, reported the striking efficacy of another BRAF inhibitor, PLX4032 (now
Vemurafenib), in inducing a partial or complete tumor regression and prolonged animal survival, in a
dose-dependent manner and without signs of toxicity [25–27]. The positive results obtained by these
studies laid the foundation for the Food and Drug Administration (FDA)-approval of Vemurafenib
for the treatment of BRAFV600E mutated metastatic melanoma patients, which resulted effective in
significantly prolonging the progression-free survival compared with standard therapies [28].
An additional example of a successful translational study from mice to humans is the one
demonstrating the anti-tumor activity of another BRAF inhibitor, the Dabrafenib [29], against human
melanoma xenografts. These data laid the foundation for Dabrafenib clinical evaluation that finally led
to its FDA approval in 2013 for the treatment of metastatic BRAF-mutated melanoma patients [30,31].
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2.2. Pre-Clinical Modeling of NRAS in Mice
While activating mutations in the BRAF gene were discovered in around 50% of melanoma
patients, mutations in NRAS account for 21–28% of melanomas. The vast majority of these mutations
(around 84%) are localized in codon 61 (glutamine to arginine; NRASQ61R), while only a small fraction
(around 7%) is contained in codon 12 (glycine to aspartic acid; NRASG12D) [32]. As for the BRAFV600E,
also the importance of NRAS mutations in melanoma development has been studied in GEMMs.
In 2005, Ackerman and collaborators demonstrated in vivo that the expression of the constitutively
active NRASQ61R in mouse-melanocytes under the tyrosinase (Tyr) promoter induced cutaneous
melanomas in mice, even if with low penetrance and long latency. However, the crossing of these mice
into Ink4a/Arf-null background demonstrated the importance of the cooperation of these mutations,
since Tyr-NRASQ61K, Ink4a/Arf mice developed metastatic melanomas at higher penetrance (83%)
and shorter latency, with lung and liver metastasis [33]. Next, the contribution of activated NRAS
oncogene in melanomagenesis, alone or in combination with p16Ink4 or liver kinase B1 (Lkb1) or
CDKN2A depletion, was corroborated by other groups [34–36].
Again, xenograft models were then used to test the efficacy of targeted therapies in NRAS
mutated melanomas. However, the direct targeting of NRAS with small-molecule inhibitors is a
quite complex approach that has been mostly ineffective, even if the search of a clinically applicable
direct RAS-targeted therapy is still active nowadays [37,38]. Since RAS activates the MAPK signaling
pathway, the idea to overcome the direct targeting of NRAS by hitting the RAS-MAPK downstream
effectors was pre-clinically tested in xenograft models of NRAS mutated melanoma. These experiments
laid the foundation for its application in human clinical trials [39–42].
2.3. Pre-Clinical Modeling of NF1 in Mice
The tumor suppressor gene NF1, coding for the neurofibromin protein, has recently emerged as
one of the key drivers of melanoma, showing a high-frequency of mutations (12–18% of all melanoma
cases) [43,44]. In particular, inactivating NF1 mutations are present in 46% of melanomas expressing
wild-type BRAF and RAS [44] and are more commonly observed in chronically sun-exposed skin,
desmoplastic melanomas [45,46]. The GTPase-activating domain of NF1 acts as a direct negative
regulator of RAS by converting RAS-GTP in RAS-GDP, thus inhibiting downstream RAS signaling.
Some missense mutations in NF1 can abolish its normal RAS-GTPase activity with a consequent
deregulation of the RAS/MAPK pathway, leading to melanomagenesis.
Thanks to the generation of a unique GEMM carrying a conditional inactivating mutation in
NF1 gene and a conditional activating BRAFV600E mutation (Tyr::CreERT2; BrafCA/+; Nf1flox/flox
mice), Maertens and colleagues reported that NF1 loss cooperates with BRAF mutation to drive
melanomagenesis. Indeed, they described a significant increase in melanoma development rate in
Tyr::CreERT2; BrafCA/+; Nf1flox/flox mice compared to the BRAF-mutant counterpart [47]. Moreover,
NF1 loss in presence of mutant BRAF leads to an ever-increasing hyperpigmentation of the skin
and massive melanin deposition with dermis expansion in these mice because of melanocyte
hyperproliferation [47]. These data are consistent with previous findings on a transgenic mouse
model of NF1 haploinsufficiency, in which melanocytes show higher MAPK and melanin synthesis
gene activities than their wild-type counterpart [48].
Thus, NF1 can be qualified as a potent tumor suppressor in melanomas. Furthermore,
BRAF/NF1-mutant tumors have turned out to be insensitive to BRAF inhibitors such as Vemurafenib,
compared to single BRAF-mutant tumors, both in in vitro and in vivo experiments. This strong
implication of NF1 in the drug resistance acquisition is reinforced by the evidence that NF1 mutations
are coupled with drug resistance also in a human setting, in BRAF-mutant melanoma patients [43,49,50].
These data suggest the importance of a patients’ selection for an effective treatment.
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2.4. The Use of Patient-Derived Xenografts for Targeted Therapies
Almost every patient develops a resistance to targeted therapies. The possibility to gain an insight
into the mechanisms of resistance development and possible overcoming is of paramount importance.
As a step in this direction, mouse models based on patient-derived tumor xenograft (PDX) have been
established [51–53]. The idea is to engraft the fresh primary melanoma derived from a patient who is
going to be treated directly into immunodeficient mice and to perform a “co-clinical” trial, treating
mice ahead or concurrently with the patient. The results obtained from the PDX trial could help in
selecting the most accurate treatment for each melanoma patient.
Of course, to be relevant to study the predicted clinical response to therapies, these PDXs should
faithfully represent the features of the original patient‘s tumor. For this purpose, melanoma PDXs
have been extensively characterized at genomic and clinical-pathological levels.
Several studies revealed a similar genetic pattern between the patients’ original tumors and
successive “xenotransplantations” in mice [52,54]. Moreover, Quintana and collaborators demonstrated
a comparable metastatic behavior of PDXs derived from patients with stage IIIB/IIIC melanoma,
showing that 95% of the generated PDX exhibited metastases to distant organs analogous to those
found in the corresponding patient [55]. Interestingly, several reports showed that the use of PDX
faithfully reproduces patients’ response to targeted therapies. Thanks to the possibility of generating
dozens of mice sampling serial biopsies from a single melanoma patient, a better reproduction of
the heterogeneity of the tumor and of the multiple clonally derived mechanisms of resistance to
targeted-therapies could be achieved in PDXs [56]. Therefore, PDXs with acquired resistance to BRAF
inhibitor can be exploited to pre-clinically identify effective double and triple combination therapies,
rationally guiding the use of second-line therapies in patients on the basis of the clinical activity
observed in the “personalized” xenograft [56–59].
Obviously, the possibility to identify the most effective personalized medicine by performing
“clinical trial” in PDX models have provoked a great enthusiasm. Nevertheless, this process has some
important limitations. One is a matter of time. Indeed, generation of PDXs from a patient’s tumor
is not always successful, and when the xenograft develops, it can take several weeks to months to
generate sufficient numbers of mouse “avatars”, a time frame that many patients do not have [57,59].
Secondly, since PDXs are generated by implanting human melanomas in immunocompromised mice,
they are not good pre-clinical models to evaluate the now well-known important role of the interaction
between the tumor and the immune system [60] and to study the efficacy of novel immunotherapeutic
approaches [61,62]. Lastly, in 2017, Ben-David and colleagues, by performing a comprehensive genomic
analysis evolution in a collection of more than 1000 PDXs of different cancer types, questioned the
reliability of PDXs for modeling human therapeutic response [63]. Indeed, their results showed that
copy number alterations (CNA) in PDXs and parental lesions are substantially different and that the
two hosts follow a distinct selection pressure and a different clonal evolution [63].
2.5. The Use of the B16 Model to Elucidate the Role of Circulating Exosomes in Metastatic Melanoma
The findings of the presence of extracellular vesicles, in particular of EXs, capable to act as
vehicles for the transfer of bioactive molecules between cells, have revolutionized the knowledge of
the intercellular communication field [64,65]. Recent advances in cancer research have highlighted
interest in the function of EXs as possible players for tumor onset and progression. Indeed, in the
oncology field, EXs are known to perform a wide range of fundamental biological and functional roles
that influence tumor growth, invasion, metastatization, angiogenesis and stem-cell renewal [66–68].
Several studies have shown that melanoma patients have an increased number of EXs in their plasma
which could play a role in tumorigenesis and in malignant progression [69]. Particularly, malignant
melanoma is characterized by a metastatization process that involves lymphatic dissemination of
tumor cells inducing reactive lymphangiogenesis prior to metastatization and eventually promoting
the establishment of the pre-metastatic niche within downstream lymph nodes [70,71]. Consequently,
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melanoma cell-derived EXs could play a critical role at this level, being involved in the alteration of
the angiogenic microenvironment of the tumor, eventually resulting in melanoma cells diffusion.
In this regard, the use of the B16 transplantable cell line has allowed elucidating the role of
melanoma EXs in promoting disease progression. This widely used cell line was derived from
a spontaneous melanoma arose at the base of the ear in a C57BL/6J mouse. B16 transplantable
tumors let the study of tumor growth and/or metastatization in immunocompetent syngeneic
mice, preserving the interactions between cancer cells and the microenvironment. Several clones
with different proliferative and metastasizing capability have been derived from the original cell
line [72]; among them, the B16-F10 clone is greatly malignant, with a high metastatic potential to
visceral organs, particularly to the lungs. Taking advantage of the in vivo study of EXs derived from
B16-F10 cells injected in mice, Peinado and collaborators demonstrated that melanoma EXs could
educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET signaling.
This observation obtained from pre-clinical studies was then transferred into the human clinical setting,
validating the higher level of MET and phospho-MET in circulating EXs isolated from stage III and
IV melanoma patients as compared to controls. The results observed suggest that MET expression
in circulating EXs could be considered as a new predictor or early marker of metastatic disease in a
human clinical setting [73].
3. The Weakness of Mouse Models: Testing Immunotherapy against Melanoma
Thanks to the recent advances in deep sequencing, melanomas are now classified at the molecular
level depending on the mutational status of their major oncogenic drivers (BRAF, NRAS, and
NF1), and are considered as “triple-negative” when no mutations are present in these genes [74].
Accordingly, several targeted inhibitors have been developed and exploited for human melanoma
patients’ management. However, after an initial effective response, almost inevitably patients acquire
resistance to these targeted therapies through multiple mechanisms [75–77] and this still remains a
major problem. Novel strategies are therefore urgently needed to overcome resistance to therapies.
The inherent immunogenicity and the potential role played by immunological events in melanoma
natural history have motivated researchers to appraise immunotherapeutic approaches in order
to potentiate patients’ own immune system to fight against melanoma cells. When the word
“immunotherapy” comes out, the straight thought goes to checkpoint inhibitors (CIs), i.e., monoclonal
antibodies directed against the Cytotoxic T Lymphocyte Antigen (CTLA-4) and the Programmed Cell
Death Receptor-1 (PD-1) or its ligands. CIs release the brake of the immune system, potentiating
patients’ immune cells to fight against the tumor and resulting in impressive clinical benefits.
The introduction of the anti-CTLA-4 Ipilimumab in 2011 [78,79], followed by the two anti-PD-1
inhibitors, Nivolumab and Pembrolizumab in 2015 [80–82] for melanoma patients’ management
has been revolutionary in the immune-oncology field. Clinical trials based on the combination of
Nivolumab and Ipilimumab have been recently started, showing better results for the combinatorial
approach as compared to CI monotherapy [83,84]. Indeed, with the combination of Nivolumab
and Ipilimumab, an overall response rate of 61% was achieved as respect to 11% for Ipilimumab
alone, with a progression-free survival of 11.5 months for the combinatorial approach, versus 6.9 and
2.9 months for Nivolumab and Ipilimumab alone, respectively [84]. However, most patients exhibit
innate resistance to CIs and suffer from disease progression or severe toxicity. Therefore, improvement
and new therapies are needed to “raise the tail” on the survival curve of patients and cancer vaccines
may “fuel the engine” and prepare the patient to better respond to CIs.
For the pre-clinical testing of novel cancer immunotherapies, animal models of melanoma
have always been exploited. However, if mouse models have undoubtedly contributed to our
understanding of molecular mechanisms of melanoma carcinogenesis and to the importance
of molecular targeted-therapies, their value in predicting and translating the effectiveness of
immunotherapeutic strategies in clinical trials remains controversial. Indeed, over the last years,
despite the existence of several successful immunotherapeutic strategies in immunocompetent mouse
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models, their translation to human clinical oncology failed because of unacceptable toxicity or a lack
of efficacy [9,85,86]. Currently, no melanoma vaccine has been approved as a standard treatment for
melanoma patients. Possible reasons for the failure to provide benefits could include poor vaccine
antigen immunogenicity, ineffective way of vaccine administration and wrong choice of the pre-clinical
model. Indeed, despite the unquestionable importance of murine models in human cancer research,
the 95% similarity of mouse and human genes cannot compensate for significant species differences in
physiology, anatomy, metabolism, biochemistry, pharmacokinetics, and toxicokinetics [87]. Moreover,
individual genetic sensitivities, immunologically mediated phenomena, and idiosyncratic reactions
in human patients are difficult to reproduce in mouse models. These aspects could be altogether
responsible for the inefficient translation of good pre-clinical immunotherapeutic results in new
effective immunological therapies for patients. Pro and cons of pre-clinical mouse models of melanoma
have been summarized in Table 1.
Table 1. Strengths and weaknesses of the translational value of melanoma pre-clinical models.
Model Strengths Weaknesses References
In vitro Cultured cell lines
X Easy to handle
X Major reproducibility
X Lack of
three-dimensional architecture
X Absence of interaction with the
microenvironment and with the
immune system
X No heterogeneity
Brandner et al., 2013 [4]
Turley et al., 2015 [5]
Genetically
Engineered
Mouse Model:
BRAFV600E;
NRAS; NF1
X Specific gene mutation
X Combination of multiple
gene mutations
X Functional
immune system
X Stepwise
tumor progression
X Long latency
X Incomplete penetrance
X Different anatomy, physiology
and biochemistry compared
to human
X Lack of different
genetic background
Perna et al., 2015 [22]
Talmadge et al., 2007 [87]
Transplantable
tumor model
X Functional
immune system
X Tumor interaction with
the microenvironment
X Metastasis formation
X Less predictive for the
clinical translation
X Different anatomy, physiology
and biochemistry compared
to human
X Not properly reproducing the
interactions between cancer
cells and the immune system
Riccardo et al., 2014 [7]
Talmadge et al., 2007 [87]
Patient-derived
xenograft in
immunodeficient
mouse models
X Use of human
tumor samples
X Heterogeneity
X Metastasis formation
X Possibilities for
“co-clinical trials”
X Study of drug resistance
X Absence of interactions with the
immune system
X Long latency for tumor growth
X Different tumor evolution as
compared to parental lesion
Hidalgo et al., 2011 [57]
Krepler et al., 2016 [59]
Hylander et al., 2013 [60]
Pickup et al., 2014 [61]
Hartsough et al., 2016 [62]
Ben-David et al., 2017 [63]
In vivo
(Client
owned)-Dogs
X Shared environment
with humans
X Spontaneous
tumor formation
X Functional
immune system
X Recurrence
and metastasis
X Different
genetic background
X Poor knowledge and
understanding of the
immune system
Riccardo et al., 2014 [7]
Riccardo et al., 2016 [8]
Pre-Clinical Testing of Immunotherapies in Mice
Melanoma was the first model to reveal CD4+ and CD8+ cellular specificity to cancer
differentiation antigens gp100 and tyrosinase [88,89], suggesting the immunogenicity of the tumor and
the ability of the patient’s own immune system to recognize and activate a specific immune response
against cancer cells. A great deal of effort has been then put into identifying specific melanoma
associated antigens (MAA) to trigger an effective anti-cancer immune response. In this scenario,
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other melanocyte differentiation antigens, such as MART-1, and cancer-testis antigens, such as MAGE
and NY-ESO, were identified [90–93]. Since then, tons of pre-clinical studies have been performed
for the evaluation of the anti-tumor potential of different approaches (i.e., dendritic cells vaccines,
peptide vaccines, DNA vaccines and so on) against these well-known MAAs. Almost the totality
of these pre-clinical studies has been performed immunizing mice and injecting subcutaneously or
intravenously, in a preventive or curative setting, the B16 or B16-F10 melanoma cell lines. Thanks to
successful studies performed in this pre-clinical model, several cancer vaccines have been tested, alone
or in combination with CIs, in clinical trials [78,94–96].
Starting from the observation that murine dendritic cells (DC)-derived EXs were able to induce an
antigen-specific CD4+ and CD8+ response in vitro, some pre-clinical studies have been carried out in
the B16 mouse model using DC-derived EXs-based vaccination strategies. These EXs are characterized
by the expression of several immunologically relevant components, such as MAA-derived peptides
in association to MHC class I and II molecules, and co-stimulatory molecules [97,98]. When used to
vaccinate mice, a significant protective anti-cancer immunity was induced against a B16 melanoma
tumor [99,100]. Escudier et al. in 2005 turned these pre-clinical approaches in a clinical study realizing
the first-in-human Phase I trial demonstrating the feasibility of using DC-derived EXs pulsed with
MAA-derived peptides for the immunization of stage III/IV melanoma patients [101].
However, in human melanoma patients, the effectiveness of cancer vaccines developed in the
B16 mouse model, is only modest, reflecting the difficulty of translating results from mice to humans.
Indeed, it can be speculated that the tumors induced by B16 cells transplanted in syngeneic mice do
not completely reproduce the cancer-immune system mutual interactions that in humans take place
over longer periods as compared to what happen in the transplantable model. This limitation strongly
pushes the scientists towards the search for more sophisticated and more valuable translational
pre-clinical models and hence the concept of comparative oncology became apparent.
4. The Dog Revolution: Canine Tumors as Pre-Clinical Models for Translational Immunotherapy
It was in 2003 that the National Cancer Institute’s Center for Cancer Research promoted the
Comparative Oncology Program to foster the use of naturally occurring cancers in pet animals, dogs
in particular, as models of human cancer [102]. Soon after a European initiative with a similar
purpose—the LUPA project—was launched [103]. Since then, several investigations have been
performed to compare the naturally occurring tumors in dogs with the human counterparts [7,104,105].
One of the most obvious advantages of canine versus murine models is that dogs spontaneously
develop tumors with the same anatomic and physiologic characteristics of human neoplasms, growing
over long periods of time in presence of an intact immune system that could deeply interact with
cancer cells, shaping the tumor development and progression as occurs in humans. Moreover, pets and
owners share the same environment and are exposed to the same carcinogens; a fundamental condition
which drives tumor development. The natural evolution of canine tumors follows the human one,
with the development of recurrences and metastasis to the same relevant sites, mimicking better than
any other pre-clinical model the step-wise progression of human tumors. Canine cancers are more
comparable with human neoplasms in terms of size and cell kinetics. Moreover, the inclusion of canine
patients from different breeds in clinical trials provides a background of genetic diversity similar to
what is seen in human populations.
At the same time, even if there is still a lack of comprehensive investigations, some attempts
to compare the anatomical and functional development of the immune system in humans and dogs
have been made [106–110]. Interestingly, even if not completely mature to react against the external
stress, the immune system of dogs is fully developed before birth, just like happens in humans.
Moreover, living in the same environments, and consequently being exposed to the same pathogens and
commensals, dogs shares with their owners the typical regulatory T-cell responses which accompany
the maturation of the immune system in response to postnatal stimulation. Additionally, the major
immune subsets populations, including CD4+, CD8+, CD90+ cells and DC have been characterized in
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dogs and a significant homology with humans has been demonstrated [111,112]. Conversely, dog NK
cells have proved more difficult to be characterized [113]. Interestingly, as largely demonstrated for
human patients, the phenotype of lymphocytes in the peripheral blood and tumor microenvironment of
dogs with cancer have been linked with prognosis [114,115]. As well, a consistent homology between
canine and human immunoglobulins have been demonstrated [116]. All these data reinforce the
important homology between dog and human immunobiology, especially in cancer. Of note regarding
the immunotherapy studies, the expression of checkpoint molecules, including CTLA-4 and PD-1, has
been observed on peripheral blood lymphocytes of several canine patients affected by mastocytoma,
melanoma, and renal cell carcinoma. Studies using canine tumor biopsy samples and a human
monoclonal antibody that cross-reacts with canine PD-L1 confirm expression of PD-L1 on a number
of canine tumors [117,118]. On this basis, studies to explore immune checkpoint blockade in dogs
are now under development and a recent clinical trial with a canine-chimeric monoclonal antibody
against canine PD-L1 showed a response, even if limited, in dogs with advanced melanoma [119].
All these results make dogs a priceless model for translational immunotherapeutic studies, strongly
suggesting that the evaluation of the efficacy of novel immunotherapies in canine patients may be
strongly predictive of their clinical efficacy in a human oncological setting (Table 1) [7,8,107].
In the last decades we are witnessing a real “dog revolution” with a far-reaching change in the
immune-oncology field: there is an increasing awareness regarding the problem of cancer in canine
patients that is becoming a serious challenge as in humans and more and more owners are now
demanding advanced care options for their affected dogs [102]. This could represent a turning point
for the development of innovative immunotherapies that could benefit canine patients and that at the
same time could be rapidly translated to the human clinical setting.
Among the canine tumors “under the microscope” of the comparative oncology, melanoma is one
of the most noteworthy.
4.1. Canine Melanoma
Canine melanoma is of strong interest in the comparative oncology because it is a spontaneous,
highly aggressive tumor that develops over a long period of time in an immunocompetent
microenvironment, as in human patients. Canine melanoma is a relatively common tumor in
dogs, with a higher incidence in Cocker Spaniel, Poodle, Pekinese, Gordon Setter, Chow Chow,
Golden Retriever, mixed-breed dogs, and Dachshund compared to Boxers and German Shepherds
where the melanoma frequency is lower [120]. This suggests that a genetic component is involved
in canine melanoma development. Melanoma in dogs can affect different anatomical sites as
lips, oral cavity, skin and digit/footpad, being oral melanoma the most aggressive type [105].
Accumulating evidences have highlighted the strong similarities between canine and human
melanomas: overlapping cytological, histopathological and architectural features of the tumors
have been described for both species [7,105,120,121]. Moreover, several molecular abnormalities
and signaling pathways described in specific human melanoma subtypes can be found in canine
melanoma, including phosphorylated forms of AKT and ERK1/2, alterations of the receptor tyrosinase
KIT and PTEN [104,122,123]. It is noteworthy that the BRAFV600E mutation has not been detected in
canine melanomas, suggesting that melanoma-bearing dogs are an ideal model for non-cutaneous
or UV-independent melanomagenesis [124]. Even though in humans, melanomas are prevalently
cutaneous, they could arise from tissues other than the skin, including the uvea of the eye (5.2%) and
within mucous membranes (1.3%), with a similar incidence independently from the phototypes
and therefore with a higher incidence in many part of the world [125,126]. And also, among
human cutaneous melanomas, there is a subgroup characterized by the lack of the most common
recurring mutations of BRAF, N/H/K-RAS, or NF1, which are referred to as “triple negative”
or “triple wild-type” subtype [74]. This triple negative molecular genotype is also a feature of
mucosal melanomas, which behave more aggressively and have the worst prognosis as compared to
other melanoma subtypes [127]. Therefore, for their characteristics, canine oral melanomas have
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been proposed as invaluable resources for in vivo investigation of mucosal and triple-negative
melanoma [128].
Canine oral melanoma accounts for 30–40% of all oral tumors, estimating up to 100,000 diagnoses
each year in the USA [104,105]. It is the most exploited for comparative oncology studies due to its
highly metastatic attitude, with 80% of dogs presenting tumor invasion in different organs, including
regional lymph nodes and lungs, which are relevant sites for melanoma metastatization in human
patients [104,105]. Similarly to the poor prognosis of human malignant melanoma patients, the median
survival time of dogs affected by oral melanomas is very short, being of 200 days after diagnosis, with
a high mortality rate because of recurrences and metastasis [7,129]. Standard therapies are the same
as in human patients i.e., mostly surgery, radiotherapy and/or chemotherapy. For canine patients,
surgery and radiotherapy are the main treatment options for local control of the tumor, which occurs
in about 75% of treated dog. However, the 1-year overall survival is less than 30% due to metastasis
development [129]. For this reason, systemic chemotherapy could be considered as a valid option even
if it has very little, if none, benefits in terms of clinical outcome as compared to the local control of
the disease [130]. Therefore, from the clinical point of view, innovative and more effective treatments
are still needed for both canine and human melanoma, because of their chemo- and radio-resistance.
On one hand, already approved human therapies (i.e., CIs) could be used to treat also canine melanoma,
while on the other, new therapies developed in this excellent translational melanoma model could be
speedily translated for the management of human patients.
4.2. Immunotherapy in Canine Melanoma
Following the ambition to develop new effective treatments, several groups performed veterinary
clinical trials evaluating the anti-tumor potential of different immunotherapeutic strategies mainly
focused on cytokine-based or antigen-based approaches.
The anti-tumor potential of several cytokines such as interleukin 2 (IL-2), interferon γ (IFN-γ),
granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-12 and IL-18 have been evaluated
for the treatment of canine melanoma patients. Different approaches have been used to evaluate the
effectiveness of these cytokines-based therapies, ranging from administration of genetically engineered
xenogeneic or autologous cytokines-producing tumor cells, plasmid lipofection or naked plasmids
administration. In general, all these studies demonstrated the potential of these immunotherapeutic
approaches in prolonging survival of canine melanoma patients when applied in an adjuvant setting.
One of the pioneering work was published more than 20 years ago by Quintin-Colonna and
collaborators, describing the efficacy of repeated local injections of human IL-2-genetically engineered
xenogeneic cells at the primary tumor site after its surgical removal in association to radiotherapy [131].
A few years later, Hogge and coworkers demonstrated the potential of the intradermal delivery of
irradiated autologous tumor cells engineered to produce the human GM-CSF in canine melanoma
patients after the surgical resection of the tumor [132]. Since then, several additional veterinary trials
have been performed evaluating the potential of these two cytokines alone or in combination with
“suicide genes” such as the herpes simplex virus thymidine kinase (HSV-TK) or with IFN-γ [133,134].
Since the 1980s, the anti-tumor potential of the same cytokines described above have been
investigated in large-scale clinical trials for the treatment of human melanoma patients [135–137],
leading to the FDA approval of IL-2 for cancer treatment of melanomas that are generally refractory to
standard therapy, and to the extensive testing of other cytokines, including GM-CSF, IL-12, and IL-18
for patients with advanced cancer.
For both humans and dogs, even if it is noteworthy that some patients with disseminated disease
achieved durable clinical benefits, the toxicities of these approaches suggested the need of identifying
a better therapeutic schedule for the treatment of both species.
A different immunotherapeutic strategy could be that focused on antigen-based therapies, mostly
using DNA vaccines against MAA shared between canine and human melanoma patients. The most
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common MAA investigated in veterinary clinical trials are the tyrosinase and gp100 antigens, alone or
in combination with cytokines [138–142].
A first Phase I pilot veterinary trial exploiting the safety and the anti-tumor potential of a
xenogeneic DNA vaccine coding for the human tyrosinase in dogs affected by advanced malignant
melanoma was conducted in 2003 by Bergman and collaborators [138]. This small study suggested for
the first time that the intramuscular anti-tyrosinase DNA vaccination was safe in dogs and endowed
with a clinical potential, laying the foundation for further investigations. Later on, additional veterinary
trials demonstrated that this DNA vaccination strategy could indeed have a therapeutic efficacy with
better results in stage II/III local-controlled canine melanoma patients [140,143]. These positive
results, along with the demonstration of the induction of a specific anti-tyrosinase immune response in
some DNA vaccinated dogs [139], led, in 2010, to the approval by the United States Department of
Agriculture (USDA) of the first anti-human tyrosinase DNA vaccine (Oncept, Merial) for the treatment
of melanoma affected dogs. Moreover, thanks to these veterinary results, a rapid translation of the
proposed therapeutic approach to the human clinical setting was achieved. Indeed, soon after, clinical
trials in human advanced melanoma patients started as well, exploiting the same strategy of xenogeneic
DNA vaccination against the tyrosinase antigen [144,145].
However, with the coming out of the most recent results from multiple veterinary trials including
a large canine melanoma population, the therapeutic efficacy of Oncept has been questioned [141,146].
The inconclusive results about the therapeutic effectiveness of Oncept in dogs could be related to the
feature of the target antigen and to the design of the clinical trials, which included both tyrosinase
positive and negative canine patients. In-human trials, the safety and the immunogenicity of the
vaccination protocol were proved. However, as well as in canine patients, a significant clinical activity
was not reached, confirming a comparable outcome in trials performed in the two species.
Nevertheless, the approval of Oncept as the first anti-cancer DNA vaccine and the demonstration
of the safety and immunogenicity of xenogeneic DNA vaccination both in dogs and humans have
spurred several groups and us to investigate the translational efficacy of the immune-targeting of other
antigens relevant for human and canine melanoma patients [147–149]. As a step in this direction, we
focused our attention on one of the most interesting MAA identified so far, the chondroitin sulfate
proteoglycan 4 (CSPG4). It is a prototype “oncoantigen” in human melanomas, since it has a restricted
expression in healthy/normal tissues, but a high expression on melanoma cells in almost 85% of
patients [150,151]. The CSPG4 has a key role in regulating the proliferative, migratory, invasive and
metastatizing ability of cancer cells and their chemoresistance, therefore simultaneously regulating
several processes needed for cancer development and progression. Moreover, CSPG4 expression has
been corroborated not only on differentiated cancer cells but also on cancer stem/initiating cells (CIC),
considered responsible for recurrences and metastasis, therefore making the CSPG4 an even more
interesting target for immunotherapy.
On these bases, we identified CSPG4 as a new marker for canine patients affected by spontaneous
oral melanoma [151,152]. We performed two veterinary trials to evaluate the potential of a xenogeneic
DNA vaccine coding for the human CSPG4 in canine melanoma patients affected by spontaneous stage
II-III CSPG4-positive oral melanomas. Dogs were electrovaccinated (DNA vaccination was associated
with electroporation) monthly after the surgical removal of the primary tumor, in order to prevent
recurrence and metastasis. This adjuvant vaccination was effective in breaking the immune tolerance
against the self-antigen, resulting in the induction of an immune response against the canine CSPG4
and in the significant prolongation of the survival of vaccinated patients as compared to controls
treated with conventional therapies alone [148,149].
Finally, given the importance of spontaneous canine cancers, recently circulating EXs have been
evaluated also in dogs. Canine EXs are characterized by a size range and a protein cargo similar
to human EXs [153,154]. Literature, unfortunately, provides a restricted set of information on the
investigation of canine EXs, opening up a great chance for new and interesting studies on EXs in canine
melanoma patients for translational applications.
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5. Conclusions
In conclusion, several pre-clinical models for the modelling of melanoma have been developed.
The mouse models are good examples to elucidate the relevance of specific driver genes for
melanomagenesis, further providing an indispensable platform for the pre-clinical testing of drug
efficacy and resistance mechanisms (Figure 1).Int. J. Mol. Sci. 2018, 19, x  12 of 21 
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Figure 1. Most relevant achievements in the melanoma onco-immunology field obtained in
(a) genetically engineered mouse models (GEMM); (b) immunodeficient mice xenotransplanted with
human cell lines or patient-derived tumors (PDXs); (c) immunocompetent mice challenged with
syngeneic B16 cells; (d) canine patients affected by spontaneous melanoma.
Nonetheless, in the tumor immunology field, given the complexity of melanoma and immune
system interactions, pre-clinical mouse models of cancers have been considered poor prognostic, being
not predictive of the results in the human clinical setting, as shown by the high rate failure of their
translation in the human clinics.
It is nowadays widely recognized that spontaneous cancers in dogs represent a highly translational
model. They offer the opportunity to investigate the clinical potential of novel immunotherapies in a
comprehensive way (Figure 1), including the “scaling up” of doses, taking into account the presence
of a complex and long-lasting interaction between the tumors and immune cells, and the possibility
of long-term assessment of efficacy and toxicity. All these features may allow the building of solid
foundations for the rapid translation of the results from melanoma canine patients to human melanoma
patients’ management, with a benefit for both species.
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